In the evolving field of biochemical research, specific molecular structures often garner significant attention due to their unique properties. Among these, the GV1001 peptide sequence stands out as a subject of intense scientific inquiry. Often categorized as a synthetic telomerase-specific peptide vaccine, it represen The novel vaccine peptide GV1001 effectively blocks β ts a precise arrangement of building blocks that researchers utilize to explore various biological interactions.
Molecular Architecture of GV1001
At its core, GV1001 is a 16-amino-acid peptide. This specific chain is derived from the catalytic site of the human telomerase reverse transcriptase (hTERT) protein, specifically spanning residues 611–626. The structural integrity of this molecule is defined by the following 16-aa hTERT sequence:
H-Glu-Ala-Arg-Pro-Ala-Leu-Leu-Thr-Ser-Arg-Leu-Arg-Phe-Ile-Pro-Lys
This precise amino acid hTERT peptide fragment GV1001 demonstrates - PubMed arrangement is what distinguishes the molecule in laboratory settings. Because GV1001 A novel telomerase-derived peptide GV1001-mediated is a 16-amino acid peptide sequence of hTERT protein, it has become a standard reference point for those studying the functional properties of telomerase-derived structures.
Scientific Context and Research Applications
When reviewing literature or laboratory datasets, one will often encounter GV1001 in the context of advanced biochemical studies. It is important to note that GV1001 is a 16-amino-acid peptide that has been extensively documented in academic databases like PubMed and PMC. Beyond its primary classification, GV1001 is a vaccine peptide derived from a 16-amino-acid sequence from the active site of the enzyme, which allows researchers to investigate its potential in various experimental models.
For those interested in the technical nomenclature, the substance is also known as tertomotide. Whether referred to as peptide GV1001 or by its synonym, the molecule consistently displays the same 16-aa human telomerase reverse transcriptase (hTERT) sequence.
Key Characteristics:
* Structure: A linear chain of 16 amino acids.
* Origin: Derived from the hTERT protein (residues 611–626).
* Classification: Often investigate by JH Kim·2022·Cited by 20—GV1001, a. 16-mer peptidederived from the active site of hTERT, is composed of amino acid residues between E611 and K626 of the hTERT (EAR-. PALLTSRLRFIPK), Read more d as a synthetic telomerase-specific peptide vaccine.
* Synonyms: Known in various research archives as RIAVAX (also known as GV1001) or tertomotide.
Navigating Research Data
When analyzing GV1001 peptide treatment datasets, researchers often focus on the specific sequences involved in protein-protein interactions. The GV1001; hTERT (611–626) designation is frequently used to ensure accuracy when documenting experimental conditions.
It is noteworthy that GV1001 is a 16-amino acid peptide that exhibits high specificity. In many studies, GV1001 peptide GV1001, a 16-mer peptide, is utilized to observe how such a small structure can influence biological pathways. Because GV1001 is a 16-amino-acid vaccine peptide, it serves as a foundational tool for those exploring the mechanisms of telomerase inhibition or modulation in non-human, controlled environments.
Conclusion
The study of peptide structures requires a deep understanding of primary sequences and their functional implications. As a peptide consisting of 16 amino acids, GV1001 offers a clear, quantifiable subject for biochemical analysis. While many recognize it as GV1001, an anticancer vaccine in its historical context, modern research continues to uncover its diverse roles in experimental biology. By f Tertomotide: Uses, Interactions, Mechanism of Action ocusing on the precise 16-aa hTERT sequence, scientists can continue to refine th GV1001 peptide eir approach to utilizing this unique peptide in various laboratory applications.
*Note: This information is provided for educational and research-related purposes only. GV1001 is a chemical compound intended for laboratory use, not for human consumption or medical treatment.*